6. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) takes the sixth spot, and this is one of the more aggressive commercial-stage biotech names on the list. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is built around Amtagvi, its tumor-infiltrating lymphocyte therapy, commonly called TIL therapy. This is a highly specialized form of cancer cell therapy that uses a patient’s own immune cells to fight cancer. In a sector filled with complex science, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) stands out because it is not just a research-stage story. It already has a commercial product.
The problem is that commercial-stage does not always mean easy. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has been volatile because Amtagvi’s launch disappointed earlier expectations. That is a common challenge in biotech. Getting FDA approval is a major achievement, but approval is not the finish line. After approval, a company still has to build demand, secure reimbursement, educate physicians, manage manufacturing, support treatment centers, and convince the market that revenue can grow at a sustainable pace.
Despite the volatility, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) remains interesting because the company is still projecting stronger 2026 product revenue. Management has guided for full-year total product revenue of $350 million to $370 million, which keeps the stock relevant for investors searching for commercial-stage biotech stocks, cancer biotech stocks, cell therapy stocks, oncology stocks with revenue growth, and small-cap biotech stocks with upside potential.
The science behind Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is also part of the appeal. TIL therapy is different from many traditional cancer drugs because it uses immune cells extracted from a patient’s tumor, expands them outside the body, and then infuses them back into the patient. This makes the treatment powerful but also operationally complex. That complexity can create challenges, but it can also create barriers to entry if a company builds strong manufacturing and treatment infrastructure.
For investors, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a classic biotech debate. The bulls can point to commercial revenue, a differentiated cell therapy platform, a serious cancer market, and guidance for stronger product sales. The bears can point to launch challenges, operational complexity, cash needs, and the difficulty of scaling individualized cell therapies. That tug-of-war is exactly why the stock has been volatile.
Still, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) belongs on this list because it gives investors exposure to one of the most advanced and ambitious corners of cancer treatment. Cell therapy remains one of the biggest long-term themes in oncology, and even though the path is not smooth, the upside can be meaningful if the company proves that Amtagvi can gain traction.
For those searching for biotech stocks to buy now, high-risk cancer stocks, and commercial-stage biotech stocks under pressure, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is not a sleepy name. It is a live story, and one that could remain heavily watched as 2026 revenue performance becomes clearer.
YOU MUST READ THIS: Top 10 Small-Cap Biotech Stocks With Billion-Dollar Upside Potential
Click here to continue reading and checkout the Top 5 Small-Cap Biotech Stocks That Could Surge 100%.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
